Edgewise Therapeutics Reports Improvements In Heart Drug Trial
Edgewise shares slip after heart-disease drug trial data disappoints investors
Edgewise to sell muscle dystrophy business to Servier for up to $2.65 billion
The $3B Biotech With Two Shots On Goal